TY  - GEN
AU  - Reis,Rafael
AU  - Labat,Laurence
AU  - Allard,Marie
AU  - Boudou-Rouquette,Pascaline
AU  - Chapron,Jeanne
AU  - Bellesoeur,Audrey
AU  - Thomas-Schoemann,Audrey
AU  - Arrondeau,Jennifer
AU  - Giraud,Frédérique
AU  - Alexandre,Jérôme
AU  - Vidal,Michel
AU  - Goldwasser,François
AU  - Blanchet,Benoît
TI  - Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients
SN  - 1873-264X
PY  - 2018///1108
KW  - Acrylamides
KW  - Afatinib
KW  - Aniline Compounds
KW  - Antineoplastic Agents
KW  - blood
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Chromatography, High Pressure Liquid
KW  - Crizotinib
KW  - Drug Monitoring
KW  - methods
KW  - Drug Stability
KW  - ErbB Receptors
KW  - antagonists & inhibitors
KW  - Erlotinib Hydrochloride
KW  - Humans
KW  - Indoles
KW  - Limit of Detection
KW  - Lung Neoplasms
KW  - Piperazines
KW  - Protein Kinase Inhibitors
KW  - Pyrazoles
KW  - Pyridines
KW  - Quinazolines
KW  - Receptors, Vascular Endothelial Growth Factor
KW  - Reproducibility of Results
KW  - Sensitivity and Specificity
KW  - Tandem Mass Spectrometry
N1  - Publication Type: Journal Article; Validation Study
UR  - https://doi.org/10.1016/j.jpba.2018.05.052
ER  -